Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
Etzer Darout raised the firm's price target on Iovance Biotherapeutics to $10 from $9, while keeping an Overweight rating on the shares. This announcement was made as part of the firm's 2026 projections, where it revised its valuation targets for the biotech industry. Earlier in Q3 2025, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) highlighted a total product revenue of $68 million, which was a 13% sequential increase. The primary driver was Amtagvi sales, which reached $58 million, while Proleukin contributed ~$10 million. The company also reaffirmed its full-year 2025 revenue guidance of $250 to $300 million. Management remains optimistic about Amtagvi's growth, projecting peak US sales in advanced melanoma to exceed $1 billion. This growth is supported by an expanding network of 80+ Authorized Treatment Centers across ~40 states. A major operational shift is planned for early 2026, when Iovance will centralize all Amtagvi and clinical manufacturing at its internal facility, the I
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics (IOVA) Is Down 14.9% After Governance Scrutiny And Equity Raise Plan Is Revealed [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics (IOVA) Valuation Check After Amtagvi Outlook Reaffirmation And Governance Concerns [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA), Nutex Health, Inc. (NUTX), Lantheus Holdings, Inc. (LNTH), and Molina Healthcare, Inc. (MOH)GlobeNewswire
- Iovance Biotherapeutics: Bright Prospects For 2026 [Seeking Alpha]Seeking Alpha
IOVA
Earnings
- 11/6/25 - Beat
IOVA
Sec Filings
- 1/9/26 - Form 8-K
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- IOVA's page on the SEC website